Long Ideas - Keryx BioPharmaceuticals (NASDAQ:KERX) has been a booming success for PropThink, with the stock doubling since PropThink first got behind the Zerenex data in mid-October. And, our … Continue Reading
Read NowLong Ideas - The highlight of our week was Allergan’s ~$1B buyout of MAP Pharmaceuticals, a company that we recommended in early January. The acquisition came at a … Continue Reading
Read NowLong Ideas - Keryx BioPharmaceuticals (NASDAQ:KERX) miscalculated the timing for when its CRO (contract research organization) would deliver Phase III results for Zerenex, the company’s phosphate-binder candidate for … Continue Reading
Read NowMost Popular - The FDA will decide on Lymphoseek’s approval in April, a major catalyst for Navidea (NAVB). Interest will again build in the some-what controversial name, and … Continue Reading
Read NowLong Ideas - In medicine, there are certain watershed moments that become an enduring part of medical history, such as the discovery of penicillin, or the eradication of … Continue Reading
Read NowMost Popular - We spent the week in San Francisco for the JP Morgan and Biotech Showcase conferences, which proved invaluable for idea generation, networking, and the solidifying of some … Continue Reading
Read NowLong Ideas - PharmAthene Inc. (AMEX:PIP) announced on Thursday that the Delaware Supreme Court heard oral arguments in ongoing litigation with SIGA Technologies (NASDAQ:SIGA), and a previous ruling … Continue Reading
Read Now